bioRxiv Science⌕ Search

Biology subjects

Alcazar, O.

Publications and source records attributed to Alcazar, O..

6 recordsLinked to original sources

Effect of Immunosuppressive Drugs on Glucose-Stimulated Insulin Secretion: Concentration-Response Studies in Dynamic Perifusion Assays

Immunosuppressive drugs, which are required to maintain graft function in transplant recipients, are associated with many unavoidable side effects including posttransplant diabetes mellitus (PTDM) that involves both peripheral insulin resistance and impairment of insulin secretion. To characterize in detail the concentration-dependency of the effect of well-known immunosuppressive drugs on glucose-stimulated insulin secretion (GSIS), we performed dynamic perifusion studies with human pancreatic islets. The effect on the time-profile of GSIS has been assessed over a wide concentration range for several clinically relevant immunomodulatory therapies, including small-molecule drugs (cyclosporine, sirolimus, tacrolimus, prednisolone acetate, and loteprednol etabonate) and biologics (abatacept and anti-CD40L), plus a prospective {beta}-cell proliferation-inducing agent (harmine). While biologics showed no significant detrimental effects after one-day treatment even at relatively high concentrations (5 {micro}M), all small-molecule drugs inhibited insulin secretion in a concentration-dependent manner, although glucocorticoids showed a distinct response pattern. Calcineurin and mTOR inhibitors preserved GSIS within their therapeutic ranges but progressively distorted its time-profile at higher concentrations and completely suppressed secretion at the highest levels. Cyclosporine exhibited the least, only about 35-fold, separation between its therapeutic target (Ctarg) and half-maximal GSIS inhibitory (IC50) concentrations. Glucocorticoids did not alter the shape of the time-profile but inhibited overall insulin secretion even at therapeutic levels. Their inhibitory effect only increased slowly with concentration and did not follow a classic sigmoid pattern that has unity Hill slope. These findings establish quantitative benchmarks for immunosuppressant-induced {beta}-cell toxicity and provide a framework for optimizing immunosuppressive regimens to reduce the risk of PTDM.

pharmacology and toxicology↗

Post-Inhibitory Rebound by δ-Cells Transforms Inhibition into Excitationand Redefines Islet Plasticity.

The coordination of hormone secretion within the pancreatic islet remains incompletely understood. Here we identify post-inhibitory rebound (PIR), a transient excitatory overshoot of glucoregulatory hormones following inhibitory signaling, as a fundamental and previously unrecognized feature of islet physiology. Human islets from donors with type 2 diabetes displayed concomitantly elevated insulin and somatostatin secretion with tightly correlated dynamics, a pattern reproduced in islets from high-fat-diet-fed mice. Using a combination of cell-type-specific chemogenetic and optogenetic approaches, high-resolution triple-hormone perifusion, Ca{superscript 2} imaging, in vivo islet grafts, and physiological ligands, we demonstrate that transient {delta}-cell activation or inhibition consistently triggers rebound excitation of {beta}- and -cells. These responses generate glucose-dependent, synchronized oscillations of insulin and glucagon secretion that are partially mediated by somatostatin receptor signaling. Mechanistic insights obtained in mouse islets were recapitulated using translatable approaches in human islets, establishing the relevance of this dynamic signaling framework across species. In vivo, selective {delta}-cell modulation bidirectionally regulated systemic glucose tolerance, confirming {delta}-cell control over endocrine output. These findings support a model in which somatostatin signaling encodes hormone output through temporal dynamics rather than tonic inhibition. By reframing somatostatin as a dynamic regulator of excitability, we identify {delta}-cell-driven rebound as a mechanism that converts inhibition into coordinated endocrine output. Together, this work establishes a revised framework for intra-islet paracrine crosstalk in which temporal dynamics, rather than static inhibition, govern endocrine coordination. Significance StatementHormone secretion in the pancreatic islet has long been explained by inhibitory feedback loops, with somatostatin viewed as a static suppressor of insulin and glucagon release. Our study overturns this paradigm by identifying post-inhibitory rebound (PIR) as a dynamic property of intra-islet signaling. {delta}-cell-driven PIR synchronizes - and {beta}-cell activity, enabling adaptive, glucose-dependent hormone release and revealing that somatostatin confers system plasticity when needed. This work establishes a revised model of intra-islet paracrine crosstalk in which {delta}-cell-driven rebound dynamics, rather than static inhibition, determine endocrine coordination and system plasticity. Our discovery reframes inhibition as a rhythmic and regenerative force, positioning PIR as a potentially generalizable mechanism of excitability across biological systems. HighlightsO_LI{delta}-cells convert inhibition into excitation. Transient somatostatin signals trigger post-inhibitory rebound (PIR) in {beta}- and -cells, generating glucose-dependent synchronized hormone oscillations. C_LIO_LIProvides a mechanistic explanation for a long-standing paradox in human type 2 diabetes. Elevated basal insulin and somatostatin secretion are positively correlated; PIR explains this co-hypersecretion. C_LIO_LIAsymmetric {delta}-cell control confers islet plasticity. Stronger inhibition of -cells versus {beta}-cells enables balanced insulin/glucagon output during feeding or glucagon-skewed surges for hypoglycemia protection. C_LIO_LIMulti-scale validation across species. Chemogenetics, optogenetics, native ligands, Ca{superscript 2} imaging, in vivo grafts, and a data-informed phenomenological model demonstrate conservation from mouse to human islets. C_LIO_LIInhibition is instructive. A revised model of intra-islet paracrine crosstalk in which cell-type-specific temporal dynamics encode hormone output through rebound. C_LI Graphical AbstractSomatostatin, long considered a static inhibitor of growth and secretion, instead acts as a dynamic modulator that transforms inhibition into robust, context-dependent excitation. In the islet, amplified SST pulses drive rebound excitation to promote balanced insulin and glucagon output during anabolic demand, while dampening produces glucagon-skewed surges for protection against hypoglycemia. Inhibition in the islet is not merely suppressive but instructive, encoding future hormone output through rebound dynamics. The same pulse-rebound principle may operate in SST-rich systems such as the brain, gut, and tumors, where dynamic modulation of SST signaling confers adaptability and robustness rather than tonic suppression. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/687745v2_ufig1.gif" ALT="Figure 1"> View larger version (47K): org.highwire.dtl.DTLVardef@1a88336org.highwire.dtl.DTLVardef@3e618aorg.highwire.dtl.DTLVardef@175d94forg.highwire.dtl.DTLVardef@decf4_HPS_FORMAT_FIGEXP M_FIG C_FIG

physiology↗

Assessing the Rate-Dependence of the First Phase of Glucose-Stimulated Insulin Secretion: Dynamic Perifusion Studies with Isolated Human Pancreatic Islets

Insulin released in response to a stepwise increase in glucose (square wave) is biphasic with a transient first-phase peak of 5-10 min and a more sustained second phase. While it is usually assumed that the first phase is rate- and the second is concentration-dependent, there are no detailed investigations into the rate-sensitivity of the first phase. We performed dynamic perifusion studies with isolated human pancreatic islets in a system that allowed fully customizable glucose ramps and established the corresponding insulin secretion time-profiles with high (once-a-minute) time-resolution. We considered the first-phase release to be the excess amount of insulin in addition to what would be expected from the glucose concentration-dependent second-phase release and examined its dependence on the glucose gradient (rate of increase). The average first-phase insulin release rate calculated this way increased with the gradient and could be fitted well with a Hill-type sigmoid function having a half-maximal value around 1.25 mM/min (nHill=1.8, r2=0.96). This agrees well with our previously introduced glucose-insulin control system built on a general framework of a sigmoid proportional-integral-derivative ({sigma}PID) controller, a generalized PID controller more suitable for biological systems than classic linear ones as biological responses are always limited between zero and a possible maximum. Experimental results obtained here were used to slightly readjust the parameters of this local glucose concentration-based computational model resulting in predictions in good agreement with measured first- and second-phase insulin secretions (r2>0.90). Thus, glucose-stimulated insulin secretion (GSIS) of perifused human islets can be described well as the sum of a rate-sensitive first phase, which is a sigmoid function of the glucose gradient with half-maximal value around 1.25 mM/min, and a concentration-sensitive second phase, which is a sigmoid function of the glucose concentration with half-maximal value around 8 mM.

physiology↗

A Composite Biomarker Signature of Type 1 Diabetes Risk Identified via Augmentation of Parallel Multi-Omics Data from a Small Cohort

BackgroundBiomarkers of early pathogenesis of type 1 diabetes (T1D) are crucial to enable effective prevention measures in at-risk populations before significant damage occurs to their insulin producing beta-cell mass. We recently introduced the concept of integrated parallel multi-omics and employed a novel data augmentation approach which identified promising candidate biomarkers from a small cohort of high-risk T1D subjects. We now validate selected biomarkers to generate a potential composite signature of T1D risk MethodsTwelve candidate biomarkers, which were identified in the augmented data and selected based on their fold-change relative to healthy controls and cross-reference to proteomics data previously obtained in the expansive TEDDY and DAISY cohorts, were measured in the original samples by ELISA ResultsAll 12 biomarkers had established connections with lipid/lipoprotein metabolism, immune function, inflammation, and diabetes, but only 7 were found to be markedly changed in the high-risk subjects compared to the healthy controls: ApoC1 and PON1 were reduced while CETP, CD36, FGFR1, IGHM, PCSK9, SOD1, and VCAM1 were elevated ConclusionsResults further highlight the promise of our data augmentation approach in unmasking important patterns and pathologically significant features in parallel multi-omics datasets obtained from small sample cohorts to facilitate the identification of promising candidate T1D biomarkers for downstream validation. They also support the potential utility of a composite biomarker signature of T1D risk characterized by the changes in the above markers.

biochemistry↗

Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2

Inhibitors of the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2, which acts as a ligand-receptor pair that initiates the viral attachment and cellular entry of this coronavirus causing the ongoing COVID-19 pandemic, are of considerable interest as potential antiviral agents. While blockade of such PPIs with small molecules is more challenging than with antibodies, small-molecule inhibitors (SMIs) might offer alternatives that are less strain- and mutation-sensitive, suitable for oral or inhaled administration, and more controllable / less immunogenic. Here, we report the identification of SMIs of this PPI by screening our compound-library that is focused on the chemical space of organic dyes. Among promising candidates identified, several dyes (Congo red, direct violet 1, Evans blue) and novel drug-like compounds (DRI-C23041, DRI-C91005) inhibited the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV with low micromolar activity in our cell-free ELISA-type assays (IC50s of 0.2-3.0 M); whereas, control compounds, such as sunset yellow FCF, chloroquine, and suramin, showed no activity. Protein thermal shift assays indicated that the SMIs identified here bind SARS-CoV-2-S and not ACE2. Selected promising compounds inhibited the entry of a SARS-CoV-2-S expressing pseudovirus into ACE2-expressing cells in concentration-dependent manner with low micromolar IC50s (6-30 M). This provides proof-of-principle evidence for the feasibility of small-molecule inhibition of PPIs critical for coronavirus attachment/entry and serves as a first guide in the search for SMI-based alternative antiviral therapies for the prevention and treatment of diseases caused by coronaviruses in general and COVID-19 in particular.

pharmacology and toxicology↗

Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19

Due to our interest in the chemical space of organic dyes to identify potential small-molecule inhibitors (SMIs) for protein-protein interactions (PPIs), we initiated a screen of such compounds to assess their inhibitory activity against the interaction between SARS-CoV-2 spike protein and its cognate receptor ACE2, which is the first critical step initiating the viral attachment and entry of this coronavirus responsible for the ongoing COVID-19 pandemic. As part of this, we found that methylene blue, a tricyclic phenothiazine compound approved by the FDA for the treatment of methemoglobinemia and used for other medical applications (including the inactivation of viruses in blood products prior to transfusion when activated by light), inhibits this interaction. We confirmed that it does so in a concentration-dependent manner with a low micromolar half-maximal inhibitory concentration (IC50 = 3 M) in our protein-based ELISA-type setup, while chloroquine, siramesine, and suramin showed no inhibitory activity in this assay. Erythrosine B, which we have shown before to be a promiscuous SMI of PPIs, also inhibited this interaction with an activity similar, possibly slightly higher, than those found for it for other PPIs. This PPI inhibitory activity of methylene blue could contribute to its antiviral activity against SARS-CoV-2 even in the absence of light by blocking its attachment to ACE2-expressing cells and making this inexpensive and widely available drug potentially useful in the prevention and treatment of COVID-19 as an oral or inhaled medication.

pharmacology and toxicology↗